Scholar Rock Holding Corp

Longboard Pharmaceuticals

Summit Therapeutics

Wave Life Sciences

Edgewise Therapeutics

Viridian Therapeutics

IGM Biosciences Inc

Applied Therapeutics Inc

Praxis Precision Medicines

Zymeworks Inc

Virtus LifeSci Biotech Clinical Trials ETF

BBC tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials.

iShares MSCI Russia ETF

iPath Bloomberg Nickel Subindex Total Return ETN

VanEck Vectors Oil Services ETF

Simplify Volt Pop Culture Disruption ETF

SPDR S&P Metals & Mining ETF

We have highlighted the three ETFs each from the best and worst performing zones of first-quarter 2022.

Top and Flop ETFs of Q1

VanEck Vectors Biotech ETF

iShares Nasdaq Biotechnology ETF

ALPS Medical Breakthroughs ETF

Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALPS Medical Breakthroughs ETF (SBIO) jumped 7.54% last week.

Biotech Stocks, ETFs Starting to Look Healthier

While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare sector offers ample exposure to innovation. Among the related ETFs, the ALPS Medical Breakthroughs ETF (SBIO) is one to consider for investors seeking a line-up full [.

SBIO Is a Good Place to Be for Biotech Innovation

ARK Innovation ETF

Breakwave Dry Bulk Shipping ETF

Aberdeen Standard Physical Palladium Shares ETF 

Simplify Interest Rate Hedge ETF

We have highlighted the five best-performing zones and their ETFs halfway through first-quarter 2022.

Top and Flop ETFs At Midway Q1

Broadly speaking, mergers and acquisitions in the healthcare sector were steady in 2021, but for many investors, there weren't enough aimed at smaller biotechnology companies. As is often the case, market observers are forecasting an uptick in biotechnology consolidation activity next year.

Biotech M&A Could Finally Perk Up in 2022

If there's an asset class that's looking forward to 2022, it's small- and mid-cap (SMID) biotechnology stocks because that group dealt with a variety of headwinds this year. However, there are more reasons for investors to monitor exchange traded funds, such as the ALPS Medical Breakthroughs ETF (SBIO), beyond “things can't get much worse” sentiment.

Smaller Biotech Stocks Ready to Perk Up

This year hasn't been kind to biotechnology stocks and related exchange traded funds. The headwinds faced by these assets were ratcheted up last week when the Biden administration revealed plans to pursue lower drug prices.

Biotech Stocks Have Colds, but They Can Heal

Global X Copper Miners ETF

Invesco China Technology ETF

Emerging Markets Internet & Ecommerce ETF

Invesco S&P 500 Equal Weight Industrials ETF

VanEck Vectors Steel ETF

SPDR S&P 500 ETF Trust

Vanguard Extended Market ETF

SPDR S&P Retail ETF

Looking for the perfect partner for the world's largest ETF.

Finding Synergy With SPY

Loncar Cancer Immunotherapy ETF

Defiance Nasdaq Junior Biotechnology ETF

Pfizer

Trillium Therapeutics

SPDR S&P Biotech ETF

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

BioNTech SE

Cerevel Therapeutics Holdings Inc

CM Life Sciences II Inc - Unit

iShares Evolved U.S. Innovative Healthcare ETF

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fund directed at pharmaceutical, biotechnology and medical device companies, reported Endpoints News.

Should Investors Follow Private Equity into Life Sciences?

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Biogen

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Life Sciences Investors 

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Invesco Dynamic Biotechnology & Genome ETF

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

ARK Genomic Revolution Multi-Sector ETF

These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.

Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal

Principal Healthcare Innovators Index ETF

iShares Genomics Immunology and Healthcare ETF

Marinus Pharmaceuticals

Novus Therapeutics

Invesco DWA Healthcare Momentum ETF

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Healthcare ETFs, Stocks That Gained Double Digits Last Week

Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.

Why Small-Cap Biotech ETFs Are Good Long-Term Bets

The ALPS Medical Breakthroughs ETF (SBIO) is one of many biotechnology ETF garnering attention this year amid the race to defeat the coronavirus, but SBIO also offers investors allure that will extend beyond the pandemic. SBIO is a fresh approach relative to legacy funds in the category.

Betting on Biotech With Utility Beyond Covid-19

Novavax

Exchange-traded funds with exposure to biotech stocks rocketed higher Tuesday on hopeful news about treatments for COVID-19.

Novavax's 30% surge boosts biotech ETFs to best day in weeks

With a slew of news to start off the month and quarter, biotech equities and ETFs are moving higher on Wednesday with optimism over developments on the coronavirus vaccine front. The Dow Jones Industrial Average has rallied slightly amid the news, up 0.21%, while the S&P 500 gained 0.63% and the Nasdaq Composite climbed 85%.

Biotech ETFs Gain Amid Vaccine Optimism

ALPS Clean Energy ETF

Global X MSCI Argentina ETF

The S&P 500 is sitting on an impressive 16.36% gain with just one day left in the second quarter.

3 ETFs With Q2 Gains Of At Least 30%

Biotechnology ETFs, including the ALPS Medical Breakthroughs ETF (SBIO), are on torrid paces in the second quarter. Yes, some of that bullishness is attributable to the industry’s efforts to vanquish the coronavirus, but there’s more to the story.

Biotech ETFs in the Spotlight, Why They’ll Remain There

American Tower

Global X Robotics & Artificial Intelligence ETF

Crown Castle International

Landmark Infrastructure Partners

ROBO Global Robotics and Automation ETF

SBA Communications

The Market Speaks: 3 Mega Trends Are Happening

Amplify Online Retail ETF

iShares U.S. Home Construction ETF

WisdomTree Cloud Computing Fund

Below are four ETFs that buoyed up on strong earnings results.

4 Best ETF Charts of Q1 Earnings

This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

Biotech ETF (BBC) Hits a New 52-Week High

Biotechnology sector-related exchange traded funds led the charge on Monday, with some breaking out to new highs. Among the best performing non-leveraged ETFs of Monday, the ARK Genomic Revolution ETF (CBOE: ARKG) jumped 6.1% and Virtus LifeSci Biotech Clinical Trials ETF (BBC) surged 6.4%.

Biotechnology Sector ETFs Are Leading the Charge

News for Virtus LifeSci Biotech Clinical Trials ETF ETF (BBC)